S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Better Than Oil Stocks (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Better Than Oil Stocks (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Better Than Oil Stocks (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Better Than Oil Stocks (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Better Than Oil Stocks (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Better Than Oil Stocks (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots

Arvinas (ARVN) Stock Forecast, Price & News

$19.64
-0.15 (-0.76%)
(As of 09/29/2023 ET)
Compare
Today's Range
$19.14
$20.15
50-Day Range
$19.64
$28.21
52-Week Range
$19.14
$57.96
Volume
471,929 shs
Average Volume
325,645 shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.07

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
226.2% Upside
$64.07 Price Target
Short Interest
Bearish
6.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$32,292 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.14) to ($7.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

357th out of 972 stocks

Pharmaceutical Preparations Industry

149th out of 455 stocks


ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Price History

ARVN Stock News Headlines

Arvinas' Potential In Treating ER+, HER2- Breast Cancer
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
7 Analysts Have This to Say About Arvinas
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
What 8 Analyst Ratings Have To Say About Arvinas
Arvinas: Nothing Interesting In The Near Term
6 Analysts Have This to Say About Arvinas
Where Arvinas Stands With Analysts
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
415
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.07
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+226.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-191.63%
Pretax Margin
-178.43%

Debt

Sales & Book Value

Annual Sales
$131.40 million
Book Value
$10.61 per share

Miscellaneous

Free Float
52,121,000
Market Cap
$1.05 billion
Optionable
Not Optionable
Beta
1.72
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 63)
    Chairperson, CEO & Pres
    Comp: $1.08M
  • Mr. Sean A. Cassidy CPAMr. Sean A. Cassidy CPA (Age 53)
    CPA, M.B.A., CFO, Principal Financial Officer & Treasurer
    Comp: $683k
  • Dr. Ian Taylor Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Ronald A. Peck M.D. (Age 57)
    Chief Medical Officer
    Comp: $701.63k
  • Mr. David K. Loomis M.B.A. (Age 49)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    VP of Investor Relations
  • Dr. Randy Teel Ph.D. (Age 44)
    Sr. VP of Corp. & Bus. Devel.
  • Mr. Steve Weiss (Age 53)
    Sr. VP & Chief HR Officer
  • Dr. John A. Grosso Ph.D. (Age 66)
    Sr. VP of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 55)
    Sr. VP of Neuroscience & Platform Biology













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

15 Wall Street analysts have issued 12-month price targets for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they anticipate the company's share price to reach $64.07 in the next twelve months. This suggests a possible upside of 226.2% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN stock has decreased by 42.6% and is now trading at $19.64.
View the best growth stocks for 2023 here
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.40. The company earned $54.50 million during the quarter, compared to analyst estimates of $30.94 million. Arvinas had a negative trailing twelve-month return on equity of 55.09% and a negative net margin of 191.63%. The company's quarterly revenue was up 74.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.32) EPS.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $19.64.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.05 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 415 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -